JP7627683B2 - Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態 - Google Patents

Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態 Download PDF

Info

Publication number
JP7627683B2
JP7627683B2 JP2022505329A JP2022505329A JP7627683B2 JP 7627683 B2 JP7627683 B2 JP 7627683B2 JP 2022505329 A JP2022505329 A JP 2022505329A JP 2022505329 A JP2022505329 A JP 2022505329A JP 7627683 B2 JP7627683 B2 JP 7627683B2
Authority
JP
Japan
Prior art keywords
compound
degrees
polymorph
solvent
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022505329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542918A (ja
JP2022542918A5 (https=
JPWO2021014167A5 (https=
Inventor
スティーブン コリングウッド，
ロバート メリング，
Original Assignee
ティエムイーエム１６エー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティエムイーエム１６エー リミテッド filed Critical ティエムイーエム１６エー リミテッド
Publication of JP2022542918A publication Critical patent/JP2022542918A/ja
Publication of JP2022542918A5 publication Critical patent/JP2022542918A5/ja
Publication of JPWO2021014167A5 publication Critical patent/JPWO2021014167A5/ja
Application granted granted Critical
Publication of JP7627683B2 publication Critical patent/JP7627683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022505329A 2019-07-25 2020-07-24 Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態 Active JP7627683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910664.0A GB201910664D0 (en) 2019-07-25 2019-07-25 Novel forms of compound
GB1910664.0 2019-07-25
PCT/GB2020/051779 WO2021014167A1 (en) 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide

Publications (4)

Publication Number Publication Date
JP2022542918A JP2022542918A (ja) 2022-10-07
JP2022542918A5 JP2022542918A5 (https=) 2023-07-28
JPWO2021014167A5 JPWO2021014167A5 (https=) 2023-07-28
JP7627683B2 true JP7627683B2 (ja) 2025-02-06

Family

ID=67990591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505329A Active JP7627683B2 (ja) 2019-07-25 2020-07-24 Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態

Country Status (19)

Country Link
US (1) US12281077B2 (https=)
EP (1) EP4003960A1 (https=)
JP (1) JP7627683B2 (https=)
KR (1) KR20220087430A (https=)
CN (1) CN114585607B (https=)
AU (1) AU2020318943A1 (https=)
BR (1) BR112022001276A2 (https=)
CA (1) CA3145285A1 (https=)
CL (1) CL2022000187A1 (https=)
CO (1) CO2022002046A2 (https=)
CR (2) CR20220079A (https=)
GB (1) GB201910664D0 (https=)
IL (1) IL290071B1 (https=)
MX (1) MX2022000891A (https=)
MY (1) MY207877A (https=)
PE (1) PE20221407A1 (https=)
PH (1) PH12022550193A1 (https=)
UA (1) UA129300C2 (https=)
WO (1) WO2021014167A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145726A1 (en) 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) * 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
WO2016042114A1 (en) * 2014-09-19 2016-03-24 F. Hoffmann-La Roche Ag Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis
US11358947B2 (en) 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145726A1 (en) 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Also Published As

Publication number Publication date
CA3145285A1 (en) 2021-01-28
GB201910664D0 (en) 2019-09-11
IL290071B1 (en) 2026-02-01
AU2020318943A1 (en) 2022-03-17
JP2022542918A (ja) 2022-10-07
BR112022001276A2 (pt) 2022-03-22
KR20220087430A (ko) 2022-06-24
PH12022550193A1 (en) 2023-01-09
MX2022000891A (es) 2022-05-26
EP4003960A1 (en) 2022-06-01
US20220220074A1 (en) 2022-07-14
US12281077B2 (en) 2025-04-22
CN114585607B (zh) 2025-11-14
CL2022000187A1 (es) 2022-10-07
CO2022002046A2 (es) 2022-06-10
CR20220079A (es) 2022-06-28
CR20250316A (es) 2025-08-27
UA129300C2 (uk) 2025-03-12
CN114585607A (zh) 2022-06-03
IL290071A (en) 2022-03-01
WO2021014167A1 (en) 2021-01-28
PE20221407A1 (es) 2022-09-20
MY207877A (en) 2025-03-25

Similar Documents

Publication Publication Date Title
CA2641769C (en) Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders
EP4215520A1 (en) Tmem16a modulators
EP3697788B1 (en) Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases
US12415793B2 (en) Modulators of TMEM16A for treating respiratory disease
JP7627683B2 (ja) Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態
RU2843949C2 (ru) Твердые формы n-трет-бутил-4[[2-(5-хлор-2-гидроксифенил)ацетил]амино]пиридин-2-карбоксамида
WO2021014168A1 (en) Solid forms of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide
HK40068903A (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide
EP4003977B1 (en) Pyridine derivatives as calcium-activated chloride channel modulators
HK40067765B (zh) 用於治疗呼吸系统疾病的tmem16a的调节剂
CN116745267A (zh) 用于治疗呼吸系统疾病的苯并咪唑衍生物
CN103087137A (zh) 一种21位为硫代烃基的糖皮质激素
HK1119703B (en) Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) ethylaminoimethyl]}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders
HK1119703A (en) Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(r)-2-hydroxy-2-(8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) ethylaminoimethyl]}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250127

R150 Certificate of patent or registration of utility model

Ref document number: 7627683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150